Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Inclusion Criteria:

B-cell non-Hodgkin lymphoma (NHL) including RT and transformed FL, that warrants systemic therapy
Chronic Lymphocytic Leukemia (leukemia-cll/" >CLL), that warrants systemic therapy as defined by iwCLL (Hallek 2018)

Treatment Status:

NHL subjects: relapsed to or refractory after at least two prior standard systemic therapies (excluding antibiotics)
RT subjects: must have relapsed after or be refractory to at least two prior line of therapy for CLL/SLL or RT
CLL subjects: relapsed to or refractory after at least two prior standard therapies

Measurable disease defined as:

NHL (including SLL): at least 1 measurable disease lesion > 1.5 cm
CLL: at least 1 measurable disease lesion

Exclusion Criteria:

Prior therapy with any agent blocking the CD47/SIRPα pathway or any previous CD19 targeting therapy,
Subjects receiving cancer therapy (i.e. chemotherapy, radiation therapy, immunotherapy, biologic therapy, hormonal therapy, surgery and/or tumor embolization) or any investigational drug within 21 days of Day 1 of Cycle 1
Prior autologous SCT within 6 months.